Featured Research Search Results

Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

Clinicaltrials.gov identifier:
NCT05253651

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

Clinicaltrials.gov identifier:
NCT05417594

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04486352

Treatment
Phase 2 treatment study for recurrent endometrial cancer

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Clinicaltrials.gov identifier:
NCT02693535

Treatment
Cancer treatment study for people with advanced solid tumors

Metastatic Castration Resistant Prostate Cancer Clinical Trial

Clinicaltrials.gov identifier:
NCT03460977

Treatment
Treatment study for men with metastatic castration resistant prostate cancer

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Clinicaltrials.gov identifier:
NCT04038502

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation

Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)